Previous lines of treatment per patient
| First line . | Second line . | Third line . | Response to the previous line† . | TTP‡ . | |||
|---|---|---|---|---|---|---|---|
| Treatment* . | Response . | Treatment . | Response . | Treatment . | Response . | ||
| MATRix (4) | PD | PD | 0 | ||||
| MATRix (4) > ASCT > WBRT | CR | CR | 9 | ||||
| MTX-ARAC (3) | PD | PD | 0 | ||||
| R-MPV (3) > WBRT + ITT | CR | MATRix (4) > ASCT | CR | CR | 8 | ||
| R-MTX-ARAC (4) > WBRT | PD | PD | 0 | ||||
| R-MTX-ARAC (4) > ASCT | CR | CR | 2 | ||||
| R-MTX-ARAC (4) | PD | Resection | PD | PD | 0 | ||
| MTX-ARAC (2) > WBRT | CR | CR | 1 | ||||
| R-MTX (3) > WBRT | PR | TMZ (2) | PD | R (4) | PD | PD | 0 |
| R-MTX-ARAC (4) > ASCT | CR | WBRT | CR | CR | 3 | ||
| MATRix (4) | PD | WBRT | CR | CR | 2 | ||
| R-MTX-ARAC (3) + ITT | PD | R-ITX-VP16 (2) | PD | WBRT | CR | CR | 3 |
| MTX-TMZ (5) + ITT | CR | CR | 8 | ||||
| MATRix (4) > De-VIC | PD | PD | 0 | ||||
| MTX (17) | CR | R-TMZ (4) | PD | PD | 0 | ||
| MATRix (4) > ASCT | CR | CR | 27 | ||||
| MATRix (4) > ASCT | CR | CR | 84 | ||||
| MATRix (4) > ASCT > WBRT | PD | PD | 0 | ||||
| R-MTX-ARAC (4) | PD | PD | 0 | ||||
| MATRix (2) | PD | PD | 0 | ||||
| MATRix (4) > ASCT | CR | CR | 12 | ||||
| MATRix (4) | PD | PD | 0 | ||||
| R-MTX-ARAC (2) | PD | R-ITX-VP16 (4) | PD | PD | 0 | ||
| MATRix (4) > WBRT | CR | CR | 1 | ||||
| MATRix (4) > ASCT + IVT | CR | CR | 4 | ||||
| MATRix (4) > ASCT | CR | CR | 11 | ||||
| R-MTX-ARAC (2) | PD | PD | 0 | ||||
| R-MTX-ARAC (4) > ASCT | CR | CR | 11 | ||||
| First line . | Second line . | Third line . | Response to the previous line† . | TTP‡ . | |||
|---|---|---|---|---|---|---|---|
| Treatment* . | Response . | Treatment . | Response . | Treatment . | Response . | ||
| MATRix (4) | PD | PD | 0 | ||||
| MATRix (4) > ASCT > WBRT | CR | CR | 9 | ||||
| MTX-ARAC (3) | PD | PD | 0 | ||||
| R-MPV (3) > WBRT + ITT | CR | MATRix (4) > ASCT | CR | CR | 8 | ||
| R-MTX-ARAC (4) > WBRT | PD | PD | 0 | ||||
| R-MTX-ARAC (4) > ASCT | CR | CR | 2 | ||||
| R-MTX-ARAC (4) | PD | Resection | PD | PD | 0 | ||
| MTX-ARAC (2) > WBRT | CR | CR | 1 | ||||
| R-MTX (3) > WBRT | PR | TMZ (2) | PD | R (4) | PD | PD | 0 |
| R-MTX-ARAC (4) > ASCT | CR | WBRT | CR | CR | 3 | ||
| MATRix (4) | PD | WBRT | CR | CR | 2 | ||
| R-MTX-ARAC (3) + ITT | PD | R-ITX-VP16 (2) | PD | WBRT | CR | CR | 3 |
| MTX-TMZ (5) + ITT | CR | CR | 8 | ||||
| MATRix (4) > De-VIC | PD | PD | 0 | ||||
| MTX (17) | CR | R-TMZ (4) | PD | PD | 0 | ||
| MATRix (4) > ASCT | CR | CR | 27 | ||||
| MATRix (4) > ASCT | CR | CR | 84 | ||||
| MATRix (4) > ASCT > WBRT | PD | PD | 0 | ||||
| R-MTX-ARAC (4) | PD | PD | 0 | ||||
| MATRix (2) | PD | PD | 0 | ||||
| MATRix (4) > ASCT | CR | CR | 12 | ||||
| MATRix (4) | PD | PD | 0 | ||||
| R-MTX-ARAC (2) | PD | R-ITX-VP16 (4) | PD | PD | 0 | ||
| MATRix (4) > WBRT | CR | CR | 1 | ||||
| MATRix (4) > ASCT + IVT | CR | CR | 4 | ||||
| MATRix (4) > ASCT | CR | CR | 11 | ||||
| R-MTX-ARAC (2) | PD | PD | 0 | ||||
| R-MTX-ARAC (4) > ASCT | CR | CR | 11 | ||||
ARAC, high-dose cytarabine; De-VIC, dexamethasone, etoposide, ifosfamide, and carboplatin; ITT, intrathecal chemotherapy; ITX, high-dose ifosfamide; IVT, intravitreal therapy; MATRix, methotrexate, cytarabine, thiotepa, and rituximab; MPV, methotrexate, procarbazine and vincristine; MTX, high-dose methotrexate; R, rituximab; TMZ, temozolomide; VP16, etoposide.
Number in parentheses indicates number of chemotherapy courses.
Response to the last line of treatment before trial registration.
TTP is the time to progression since the completion of the last line of treatment before trial registration.